Chiasma (New York and Israel) is a biopharmaceutical company developing oral drugs that were previously only available by injection, providing patients with pain-free medications that are self-administered. The company’s lead product has completed Phase 3 clinical trial for the treatment of acromegaly.
|Oral Octreotide (previously called Octreolin®)
Oral octreotide is in clinical development for patients with acromegaly, a hormonal disorder that results from an excess of growth hormone. Today octreotide is typically administered by large bore intra-muscular needle injections. Oral octreotide has the potential to improve the quality of life of acromegaly patients. Phase 3 results were presented at ENDO Chicago, June 2014. More…
At Chiasma, we recognize the challenges of living with a chronic disease. We are focused on developing oral octreotide (Octreolin), an investigational drug for acromegaly. This is the only oral somatostatin analog treatment for acromegaly currently in clinical development. Phase 3 results are planned to be presented at ENDO Chicago, June 21-24, 2014. More…